Omnicell (OMCL) stock price is $35.81, up 1.19% on the day, as of Oct 19, 2026. It has a market cap of $1.63Bn and a P/E ratio of 41.75, and is classified in the Medical Devices industry (Healthcare sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap1.63 Bn
P/E41.75
P/S1.31
Div. Yield0.00
Revenue Growth (1y) (Qtr)7.45
Add ratio to table…
About
Omnicell is a healthcare technology provider that focuses on medication management automation across the continuum of care. The company develops and sells hardware software and services that automate the storage dispensing and administration of medications. Its solutions are designed to improve safety efficiency and financial outcomes for hospitals health systems pharmacies and other care providers. Omnicell’s platform includes dispensing robots inventory management tools…
Omnicell is a healthcare technology provider that focuses on medication management automation across the continuum of care. The company develops and sells hardware software and services that automate the storage dispensing and administration of medications. Its solutions are designed to improve safety efficiency and financial outcomes for hospitals health systems pharmacies and other care providers. Omnicell’s platform includes dispensing robots inventory management tools and analytics that support the vision of an autonomous pharmacy. By integrating data from its devices the company helps clinicians reduce manual tasks and devote more time to patient care. The firm operates primarily in the United States with a growing presence in international markets. Its technology supports compliance with regulations such as the Drug Supply Chain Security Act and helps address workforce shortages in pharmacy. The firm continues to invest in research and development to expand its product portfolio.
Omnicell generates revenue primarily through the sale of its medication management systems and related services. The company offers equipment such as automated dispensing cabinets robotic compounding systems and inventory management hardware. It also provides software platforms including its OmniSphere intelligence ecosystem that delivers analytics and workflow optimization. In addition Omnicell earns revenue from service contracts that cover installation maintenance training and technical support. The firm offers financing options such as leases and subscription models to help customers acquire its technology. Revenue is recognized when products are delivered or services are rendered over the contract period. The company serves a diverse set of customers including acute care hospitals ambulatory surgery centers long term care facilities and retail pharmacies.
The company manages its operations as a single operating segment for performance assessment and resource allocation decisions.
The operating segment encompasses all medication management solutions including hospital and health system systems outpatient pharmacy solutions and related services.
Omnicell competes in markets where several companies offer medication management automation and technology solutions. The firm differentiates itself by combining dispensing automation with a cloud based intelligence ecosystem that provides data driven insights across the medication use process. Its broad product portfolio covers acute care outpatient and retail settings allowing it to serve customers throughout the care continuum. The company’s long history of innovation and its installed base of devices give it a competitive advantage in securing repeat business. Omnicell emphasizes outcomes such as reduced medication errors improved workflow efficiency and better financial performance to appeal to health systems seeking value from their technology investments.
Omnicell serves hospitals health systems long term care facilities correctional institutions and retail pharmacies across the United States and in selected international markets. The company works with group purchasing organizations such as Vizient Premier HealthTrust and Advocate Health Supply Chain Alliance to reach its customers. It also has a federal supply schedule contract with the Department of Veterans Affairs allowing federal agencies to purchase its solutions. In addition Omnicell supplies its medication adherence products to pharmacies that serve patients with chronic conditions. Its customer base includes academic medical centers community hospitals and specialty pharmacy operators that rely on its technology to improve safety and compliance.
Sectors:Healthcare·TechnologySector rationaleOmnicell's primary business is the design and sale of medical devices and systems specifically for medication management, such as automated dispensing cabinets and robotic compounding systems sold to hospitals and pharmacies. While it has a substantial software component via its OmniSphere intelligence ecosystem, this software is integrated into its healthcare-specific hardware and services, justifying Technology as a secondary sector for its cloud-based analytics and workflow platforms.Industries:Medical DevicesMedical DevicesPrimaryOmnicell designs and manufactures therapeutic and surgical medical devices, specifically automated dispensing cabinets and robotic compounding systems used for medication administration. These hardware products are sold to hospitals, health systems, and pharmacies to improve safety and efficiency in medication management.Healthcare ITHealthcare ITSecondaryThe company provides the OmniSphere intelligence ecosystem, a software platform that delivers analytics and workflow optimization specifically for healthcare providers. This software is purpose-built for clinical workflows and compliance with healthcare regulations like the Drug Supply Chain Security Act.Classified using BQ-MICSCIK: 0000926326
Bull & bear
Investment Thesis
▲ Bull case
Omnicell is executing a strategic transformation from a device-centric supplier to an end-to-end medication and medical supplies management technology platform, which positions the company to capture higher-margin recurring revenue streams as healthcare systems prioritize integrated, enterprise-wide solutions. The launch of OmniSphere, a cloud-native platform with HITRUST CSF i1 certification, provides a differentiated cybersecure backbone for all products, enabling seamless integration across inpatient and outpatient settings while addressing growing customer demand for data protection standards—a value proposition that is resonating in large health system deals and driving stickiness through platform lock-in. This shift is evidenced by strong adoption of MedVision for clinic-level inventory management and MedTrack-OR for operating room RFID tracking, both designed to extend visibility and automation beyond traditional pharmacy settings into emerging care sites, thereby expanding Omnicell’s total addressable market as patient care migrates outpatient. The company’s ability to bundle these innovations into a unified platform reduces customer integration complexity and switching costs, creating a structural advantage over point-solution competitors and supporting long-term revenue predictability.
Omnicell’s financial performance demonstrates resilient execution amid macroeconomic headwinds, with Q1 2026 revenue growing 15% year-over-year to $310 million, driven by strength in connected devices, technical services, SaaS and Expert Services, and consumables—indicating broad-based demand across its portfolio. The company’s guidance upgrade for full-year 2026 non-GAAP EBITDA to $153–$168 million and non-GAAP EPS to $1.80–$2.00 reflects confidence in sustained margin expansion, supported by improving gross margins (product gross margin rose to 45.9% in Q1 2026 from 41.9% in Q1 2025) and operating leverage as higher-margin SaaS and expert services scale. Crucially, Omnicell is mitigating tariff impacts through supply chain resiliency initiatives and strategic pricing, with net tariff effects expected to decline in 2026 despite near-term headwinds, while its $350 million undrawn revolver and $239 million cash position provide liquidity to fund innovation and opportunistic share repurchases without compromising growth investments.
The company’s recurring revenue engine is gaining traction, with Annual Recurring Revenue (ARR) guidance raised to $680–$700 million for full-year 2026, up from $610–$630 million in 2025, reflecting successful conversion of product sales into service contracts, software subscriptions, and cloud-based offerings. This shift is reinforced by customer behavior: lease renewals and XTExtend upgrades are driving higher product revenue retention, while advanced services adoption is increasing among existing clients, reducing reliance on volatile capital expenditure cycles. Omnicell’s focus on solving clinical pain points—such as IV compounding safety through its newly launched robot and outpatient medication workflows via MedVision—creates tangible ROI for health systems facing labor shortages and margin pressure, making its solutions less discretionary and more essential to operational continuity, thereby insulating demand from cyclical downturns in capital spending.
Omnicell is executing a strategic transformation from a device-centric supplier to an end-to-end medication and medical supplies management technology platform, which positions the company to capture higher-margin recurring revenue streams as healthcare systems prioritize integrated, enterprise-wide solutions. The launch of OmniSphere, a cloud-native platform with HITRUST CSF i1 certification, provides a differentiated cybersecure backbone for all products, enabling seamless integration across inpatient and outpatient settings while addressing growing customer demand for data protection standards—a value proposition that is resonating in large health system deals and driving stickiness through platform lock-in. This shift is evidenced by strong adoption of MedVision for clinic-level inventory management and MedTrack-OR for operating room RFID tracking, both designed to extend visibility and automation beyond traditional pharmacy settings into emerging care sites, thereby expanding Omnicell’s total addressable market as patient care migrates outpatient. The company’s ability to bundle these innovations into a unified platform reduces customer integration complexity and switching costs, creating a structural advantage over point-solution competitors and supporting long-term revenue predictability.
Omnicell’s financial performance demonstrates resilient execution amid macroeconomic headwinds, with Q1 2026 revenue growing 15% year-over-year to $310 million, driven by strength in connected devices, technical services, SaaS and Expert Services, and consumables—indicating broad-based demand across its portfolio. The company’s guidance upgrade for full-year 2026 non-GAAP EBITDA to $153–$168 million and non-GAAP EPS to $1.80–$2.00 reflects confidence in sustained margin expansion, supported by improving gross margins (product gross margin rose to 45.9% in Q1 2026 from 41.9% in Q1 2025) and operating leverage as higher-margin SaaS and expert services scale. Crucially, Omnicell is mitigating tariff impacts through supply chain resiliency initiatives and strategic pricing, with net tariff effects expected to decline in 2026 despite near-term headwinds, while its $350 million undrawn revolver and $239 million cash position provide liquidity to fund innovation and opportunistic share repurchases without compromising growth investments.
The company’s recurring revenue engine is gaining traction, with Annual Recurring Revenue (ARR) guidance raised to $680–$700 million for full-year 2026, up from $610–$630 million in 2025, reflecting successful conversion of product sales into service contracts, software subscriptions, and cloud-based offerings. This shift is reinforced by customer behavior: lease renewals and XTExtend upgrades are driving higher product revenue retention, while advanced services adoption is increasing among existing clients, reducing reliance on volatile capital expenditure cycles. Omnicell’s focus on solving clinical pain points—such as IV compounding safety through its newly launched robot and outpatient medication workflows via MedVision—creates tangible ROI for health systems facing labor shortages and margin pressure, making its solutions less discretionary and more essential to operational continuity, thereby insulating demand from cyclical downturns in capital spending.
Omnicell’s growth narrative faces significant execution risks as it transitions to a platform-centric model, particularly given the prolonged rollout of OmniSphere, which has been in development for five years and in beta for two, yet remains in early deployment stages with limited visibility into monetization timelines or customer conversion rates from legacy systems. Despite management’s emphasis on OmniSphere as a multi-year evolution, the lack of concrete ARR or revenue contribution metrics from the platform in recent quarters raises concerns that the anticipated shift to higher-margin recurring revenue may be delayed or weaker than projected, especially if health systems hesitate to migrate due to integration complexities, change management burdens, or satisfaction with existing point solutions—potentially leaving Omnicell caught between declining legacy product sales and unfulfilled platform revenue promises.
Macroeconomic and policy headwinds are underappreciated in the company’s outlook, particularly the looming impact of Medicaid cuts and 2026 volatility in healthcare spending, which could disproportionately affect Omnicell’s core hospital and health system customers already operating under tight budgets. While management claims no observable change in customer behavior, the acknowledgment that legislative shifts “haven’t arrived yet” suggests delayed impact, and the company’s reliance on price increases to offset tariff and input cost pressures may encounter resistance as customers face stricter procurement scrutiny—especially given that gross margin expansion has been partly driven by pricing leverage rather than pure operational efficiency, making further gains difficult to sustain without volume growth or mix improvement.
Competitive dynamics are intensifying in ways that could erode Omnicell’s market position, notably in high-growth segments like IV compounding automation and outpatient clinic solutions, where the company’s claims of uniqueness are difficult to validate and may overstate differentiation; the recent hire of a Chief Pharmacy and Clinical Officer, while strategically sound, implicitly acknowledges a need to strengthen clinical credibility in product development—a signal that current solutions may not be fully aligned with frontline pharmacy workflows. Additionally, Omnicell’s substantial debt load ($168 million net of unamortized costs as of March 2026) and dependence on a limited number of suppliers for critical components increase financial and operational vulnerability, particularly if supply chain disruptions recur or interest rates remain elevated, constraining financial flexibility and increasing the cost of funding its transformation amid slowing top-line growth in certain segments. The company’s historical reliance on lease financing options also introduces credit and collection risks if healthcare providers’ balance sheets deteriorate under economic stress.
Omnicell’s growth narrative faces significant execution risks as it transitions to a platform-centric model, particularly given the prolonged rollout of OmniSphere, which has been in development for five years and in beta for two, yet remains in early deployment stages with limited visibility into monetization timelines or customer conversion rates from legacy systems. Despite management’s emphasis on OmniSphere as a multi-year evolution, the lack of concrete ARR or revenue contribution metrics from the platform in recent quarters raises concerns that the anticipated shift to higher-margin recurring revenue may be delayed or weaker than projected, especially if health systems hesitate to migrate due to integration complexities, change management burdens, or satisfaction with existing point solutions—potentially leaving Omnicell caught between declining legacy product sales and unfulfilled platform revenue promises.
Macroeconomic and policy headwinds are underappreciated in the company’s outlook, particularly the looming impact of Medicaid cuts and 2026 volatility in healthcare spending, which could disproportionately affect Omnicell’s core hospital and health system customers already operating under tight budgets. While management claims no observable change in customer behavior, the acknowledgment that legislative shifts “haven’t arrived yet” suggests delayed impact, and the company’s reliance on price increases to offset tariff and input cost pressures may encounter resistance as customers face stricter procurement scrutiny—especially given that gross margin expansion has been partly driven by pricing leverage rather than pure operational efficiency, making further gains difficult to sustain without volume growth or mix improvement.
Competitive dynamics are intensifying in ways that could erode Omnicell’s market position, notably in high-growth segments like IV compounding automation and outpatient clinic solutions, where the company’s claims of uniqueness are difficult to validate and may overstate differentiation; the recent hire of a Chief Pharmacy and Clinical Officer, while strategically sound, implicitly acknowledges a need to strengthen clinical credibility in product development—a signal that current solutions may not be fully aligned with frontline pharmacy workflows. Additionally, Omnicell’s substantial debt load ($168 million net of unamortized costs as of March 2026) and dependence on a limited number of suppliers for critical components increase financial and operational vulnerability, particularly if supply chain disruptions recur or interest rates remain elevated, constraining financial flexibility and increasing the cost of funding its transformation amid slowing top-line growth in certain segments. The company’s historical reliance on lease financing options also introduces credit and collection risks if healthcare providers’ balance sheets deteriorate under economic stress.